This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Abingdon Health’s CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities
As far as the small caps area is concerned, things remained tough work. Apart from bears enjoying the pain and occasionally the failures of others, to offset their own failings,
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
York, U.K. 7 March 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), announces the granting of an additional patent for its
London’s results season is still underway with life insurers Aviva and L&G, bookmaker Entain, cybersecurity specialist Darktrace, and sausage roll maker Greggs all set to release results this week.
OKYO Pharma (OKYO), an ophthalmology-focused bio-pharmaceutical company, announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which
York, U.K. 28 February 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract development and manufacturing organisation (CDMO), provides its half-year trading update for the six months
York, U.K. 19 December 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces the establishment of a new Long Term Incentive Plan
A round-up of the market’s news over the past week was highlighted across the Share Talk platform. The four best high risk, high reward (BOIL, HARL, PREM, AVCT) stocks to
York, U.K. 24 November 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality, rapid diagnostic tests, announces its preliminary results for the year ended